[1]吴伟权,林淑文,侯智勇*.乳腺癌基因-1、CA 125在子宫内膜癌患者中的表达及对预后预测作用的分析[J].中国计划生育和妇产科,2018,(12):27-31.
　WU Wei-quan,LIN Shu-wen,HOU Zhi-yong*.Expression analysis of breast cancer gene-1 and CA 125 in patients with endometrial cancer and its predictive effect on prognosis[J].Chinese Journal of Family Planning & Gynecotokology,2018,(12):27-31.
点击复制

乳腺癌基因-1、CA 125在子宫内膜癌患者中的表达及对预后预测作用的分析
分享到：

《中国计划生育和妇产科》[ISSN:1674-4020/CN:51-1708/R]

卷:
期数:
2018年12期
页码:
27-31
栏目:
论著与临床
出版日期:
2018-12-25

文章信息/Info

Title:
Expression analysis of breast cancer gene-1 and CA 125 in patients with endometrial cancer and its predictive effect on prognosis
作者:
吴伟权; 林淑文; 侯智勇*
东莞市人民医院妇产科
Author(s):
WU Wei-quan; LIN Shu-wen; HOU Zhi-yong*
Department of Gynecology and Obstetrics,Dongguan People's Hospital,Dongguan Guangdong 523000,P.R.China
关键词:
子宫内膜癌; 乳腺癌基因-1; CA 125; 预后
Keywords:
endometrial carcinoma; BRCA-1; CA 125; prognosis
分类号:
R 73733
摘要:
目的探讨乳腺癌基因-1（breast cancer gene 1,BRCA-1）和CA 125在子宫内膜癌（endometrial cancer，EC）组织中的表达及对患者预后的预测作用分析。方法收集2011年5月至2013年5月于东莞市人民医院诊治的58例EC患者（A组）、31例非典型增生型子宫内膜组织（B组）、13例来院体检的健康人正常子宫内膜组织（C组），采用免疫组织化学SP法检测子宫内膜组织中BRCA-1和CA 125的表达, 分析上述指标的表达差异及其对EC预后的影响。结果① BRCA-1 在A、B、C 3组中的阳性表达率分别为328 %、613 %、923 %，CA 125阳性表达率分别为741 %、484 %、0。② BRCA-1阳性表达与FIGO 分期、组织分化及淋巴结转移有关（P＜005）；CA 125阳性表达与FIGO 分期及组织分化有关（P＜005）。③ BRCA-1阳性表达患者的生存率（947 %）高于BRCA-1阴性表达患者（718 %）,差异有统计学意义（P＜005）。④ BRCA-1与CA 125在EC中表达呈负相关性（P＜005）。 结论BRCA-1与CA 125表达在EC的发生和进展过程中起重要作用, 两者表达呈负相关，通过临床BRCA-1与CA 125检测可为早期诊断和判定EC患者病情、预测预后提供参考价值。
Abstract:
ObjectiveTo investigate the expression of breast cancer gene 1(BRCA-1) and CA 125 in endometrial carcinoma and predict the prognosis of patients. Methods58 cases of endometrial cancer patients, 31 cases of atypical proliferative endometrium, and 13 cases of normal human endometrial tissue from the Dongguan People's Hospital from May 2011 to May 2013 were collected as group A,B and C. Immunohistochemical SP method was used to detect the expression of BRCA-1 and CA 125 in the three groups of endometrial tissues, and the expression differences of the above indicators and their effects on the prognosis of endometrial cancer were analyzed.Results① The positive expression rates of BRCA-1 in A, B, and C groups were 328 %, 613 %, and 923 %, respectively, and the positive expression rates of CA 125 were 741 %, 484 %, and 0 respectively② The positive expression of BRCA-1 was associated with FIGO stage, tissue differentiation and lymph node metastasis (P<005); The positive expression of CA 125 was associated with FIGO stage and tissue differentiation (P<005)③ The survival rate of BRCA-1 positive patients was higher than that of BRCA-1 negative patients (947 % vs 718 %, P<005)④ There was a negative correlation between BRCA-1 and CA 125 expression in endometrial carcinoma (P<005)ConclusionThe expression of BRCA-1 and CA 125 plays an important role in the occurrence and progression of endometrial cancer The expression of BRCA-1 and CA 125 is negatively correlated The clinical diagnosis of BRCA-1 and CA 125 can provide reference value for early diagnosis and judgment of patients' condition and prognosis.

参考文献/References:

［1］ASAKA R, MIYAMOTO T, YAMADA Y, et al. Sirtuin 1 promotes the growth and cisplatin resistance of endometrial carcinoma cells: a novel therapeutic target ［J］. Laboratory Investigation, 2015, 95 (12): 1363-1373. ［2］高慧娟，李小毛．子宫内膜癌肿瘤标志物研究进展 ［J］．广东医学，2014，35 （6）：940-942． ［3］NARDONE B, NICHOLSON K, NEWMAN M A, et al. Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients ［J］. Clinical Cancer Research, 2010, 16 (17): 4452-4460. ［4］ZHANG Q, ZHANG Q, CONG H, et al. The ectopic expression of BRCA-1 is associated with genesis,progression,and prognosis of breast cancer in young patients ［J］. Diagnostic Pathology, 2012, 7 (1): 181. ［5］包金英，张文杰．CA 125在恶性肿瘤中的临床应用 ［J］．实用肿瘤学杂志，2013，27（2）：181-184． ［6］PECORELLI S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium ［J］. International Journal of Gynecology & Obstetrics, 2009, 105 (2): 103-104. ［7］孟波，文晓燕，宋芳．子宫内膜癌组织中BRCA-1,CA 125的表达及其意义 ［J］．中国妇幼保健，2018，33（9）：2096-2099． ［8］CHIANG S, SOSLOW R A. Updates in diagnostic immunohistochemistry in endometrial carcinoma ［J］. Seminars in Diagnostic Pathology, 2014, 31 (3): 205-215. ［9］于江燕，张一琼．HER 2和BRCA-1在子宫内膜癌中的表达及其与预后的关系 ［J］．实用肿瘤杂志，2016，31（2）：145-149． ［10］海静．缺氧诱导因子-1α和葡萄糖转运蛋白-1在子宫内膜癌中的表达及其与预后的关系［J］．中国妇幼保健，2015，30（17）：2882-2885． ［11］GARG K, LEVINE D, OLVERA N, et al. BRCA-1 immunohistochemistry in a molecularly characterized cohort of ovarian highgrade serous carcinomas ［J］. American Journal of Surgical Pathology, 2013, 37 (1): 138-146. ［12］李明珠，王志启，赵丽君，等.I-II期子宫内膜癌患者复发及预后的影响因素分析 ［J］.中华妇产科杂志, 2014, 49 (6) :455-459. ［13］EOH K J, PARK H S, PARK J S, et al. Comparison of clinical outcomes of BRCA1/2 pathologic mutation, variants of unknown significance, or wild type epithelial ovarian cancer patients ［J］. Cancer Research and Treatment, 2017, 49 (2): 408-415. ［14］刘睿倩.乳腺癌基因-1和CA 125在子宫内膜癌患者中的表达及意义 ［J］.中华全科医学，2017,15（1）:88-91. ［15］孙丹，范余娟，徐红，等．子宫内膜癌中人类乳腺癌易感基因1微卫星不稳定性及其与临床病理的关系 ［J］．实用医学杂志，2015，31（22）：3717-3719． ［16］HUANG Z-l, GAO X, LUO R-z, et al. Analysis of ERCC1,BRCA-1,RRM1 and TUBB3 as predictors of prognosis in patients with nonsmall cell lung cancer who received cisplatin-based adjuvant chemothrapy:a prospective study ［J］. Oncology Letters, 2016, 11 (1): 299-305. ［17］OBAJIMI O. Lapatinib as a chemotherapeutic drug ［J］. Recent Patents on Anti-Cancer Drug Discovery, 2009, 4 (3): 216-226.

相似文献/References:

[1]胡玲,胡健蓉,徐凤仪,等.血管内皮生长因子在子宫内膜癌中的表达及其意义[J].中国计划生育和妇产科,2011,(01):0.
　HU Ling,HU Jian-rong,XU Feng-yi,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2011,(12):0.
[2]孙红敏,苑中甫.胰岛素样生长因子受体-1在子宫内膜癌组织中的表达及意义[J].中国计划生育和妇产科,2011,(02):0.
　SUN Hong-min,WAN Zhong-fu ..[J].Chinese Journal of Family Planning & Gynecotokology,2011,(12):0.
[3]田兆华,王建六.应客观评价腹膜后淋巴结切除在子宫内膜癌的治疗价值[J].中国计划生育和妇产科,2011,(03):0.
[4]陈晓丽.CD44v6、MMP-2在子宫内膜癌的表达及临床意义[J].中国计划生育和妇产科,2011,(03):0.
　CHEN Xiao-li.[J].Chinese Journal of Family Planning & Gynecotokology,2011,(12):0.
[5]梅彤,舒宽勇.CD133在子宫内膜癌中的研究进展[J].中国计划生育和妇产科,2012,(04):0.
　MEI Tong,SHU Kuan-yong* .Medical.[J].Chinese Journal of Family Planning & Gynecotokology,2012,(12):0.
[6]曹晓智,王小捷,李凤山,等.宫内膜细胞p16基因表达检测筛查子宫内膜癌的研究[J].中国计划生育和妇产科,2013,(06):0.
　Cao Xiao-zhi,Wang Xiao-jie,Li Feng-shan,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(12):0.
[7]廖娟,杨菊生,李越,等.磁共振成像在Ⅰ、Ⅱ期子宫内膜癌术前分期中的应用分析[J].中国计划生育和妇产科,2014,(06):0.
　LIAO Juan,YANG Ju-sheng,LI Yue,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2014,(12):0.
[8]姜志欣,吴玉璘.女性人乳头瘤病毒感染及相关肿瘤[J].中国计划生育和妇产科,2014,(07):0.
[9]魏丽惠.关于子宫内膜癌筛查的思考[J].中国计划生育和妇产科,2015,(01):0.
[10]张超,蒋国庆.子宫内膜癌细胞学筛查的Meta分析[J].中国计划生育和妇产科,2015,(06):0.
　ZHANG Chao,JIANG Guo-qing,[J].Chinese Journal of Family Planning & Gynecotokology,2015,(12):0.

备注/Memo

备注/Memo:
广东省科学技术研究基金项目（项目编号：C 2017034）
更新日期/Last Update: 2018-12-25